Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2008

01-12-2008 | Optimizing Breast Cancer Patient

Treatment decision-making in breast cancer: the patient–doctor relationship

Author: L. J. Fallowfield

Published in: Breast Cancer Research and Treatment | Special Issue 1/2008

Login to get access

Abstract

A diagnosis of breast cancer, whether the disease is early or advanced, can be devastating. With this in mind, constructive patient–physician relationships are essential to minimizing disease-related stress and anxiety, as patients undergo treatment and learn to cope with their diagnosis. Good communication skills are vital, and achieve measurable benefits, yet doctors receive very little training in communication. Patients may find it difficult to process large amounts of information, may not understand medical terminology, and can become confused or scared during discussions. They may need time to absorb information, and discuss it with friends and family, before treatment decisions are made. Patient awareness of treatment options is greater than ever, largely because of media exposure and the internet. Consequently, patients’ expectations and desire to be involved in treatment choice are increasing, although some patients still prefer to leave decision-making to their doctor. Information about potential side-effects and other treatment burdens is vital, if patients are to make truly informed choices. Knowing in advance what side effects may be encountered, and how to manage them, can also help to improve adherence to treatment, which is necessary for patients to gain the maximum benefit. Side effects that patients find most problematic often differ from those that most concern doctors. Individual patients have different needs and expectations that must be respected, but ensuring that they understand their diagnosis, and the expected benefits and potential risks of treatment, is the key to establishing a good therapeutic relationship and providing the best possible care.
Literature
1.
go back to reference Fallowfield L, Jenkins V (1999) Effective communication skills are the key to good cancer care. Eur J Cancer 35:1592–1597PubMedCrossRef Fallowfield L, Jenkins V (1999) Effective communication skills are the key to good cancer care. Eur J Cancer 35:1592–1597PubMedCrossRef
2.
go back to reference Fallowfield L, Lipkin M, Hall A (1998) Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom. J Clin Oncol 16:1961–1968PubMed Fallowfield L, Lipkin M, Hall A (1998) Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom. J Clin Oncol 16:1961–1968PubMed
3.
go back to reference Taylor C, Graham J, Potts HW et al (2005) Changes in mental health of UK hospital consultants since the mid-1990s. Lancet 366:742–744PubMedCrossRef Taylor C, Graham J, Potts HW et al (2005) Changes in mental health of UK hospital consultants since the mid-1990s. Lancet 366:742–744PubMedCrossRef
4.
go back to reference Fallowfield LJ (1995) Communication skills of oncologists. Trends Exper Med 5:99–103 Fallowfield LJ (1995) Communication skills of oncologists. Trends Exper Med 5:99–103
5.
go back to reference Siminoff LA (1992) Improving communication with cancer patients. Oncology 6:83–87PubMed Siminoff LA (1992) Improving communication with cancer patients. Oncology 6:83–87PubMed
6.
go back to reference Fallowfield L, McGurk R, Dixon M (2004) Same pain, less gain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 40:2403–2410PubMedCrossRef Fallowfield L, McGurk R, Dixon M (2004) Same pain, less gain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 40:2403–2410PubMedCrossRef
7.
go back to reference Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22:2461–2468PubMedCrossRef Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22:2461–2468PubMedCrossRef
8.
go back to reference Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490PubMedCrossRef Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490PubMedCrossRef
11.
go back to reference Tracy GE (2004) Breast cancer–the disease many women fear the most. SDJ Med 57(4):148 Tracy GE (2004) Breast cancer–the disease many women fear the most. SDJ Med 57(4):148
12.
go back to reference Schenck-Gustafsson K (2007) Diagnosis of cardiovascular disease in women. Menopause Int 13:9–22CrossRef Schenck-Gustafsson K (2007) Diagnosis of cardiovascular disease in women. Menopause Int 13:9–22CrossRef
13.
go back to reference Wen KY, Gustafson DH (2004) Needs assessment for cancer patients and their families. Health Qual Life Outcomes 2:11PubMedCrossRef Wen KY, Gustafson DH (2004) Needs assessment for cancer patients and their families. Health Qual Life Outcomes 2:11PubMedCrossRef
14.
go back to reference Cox A, Jenkins V, Catt S et al (2006) Information needs and experiences: an audit of UK cancer patients. Eur J Oncol Nurs 10:263–272PubMedCrossRef Cox A, Jenkins V, Catt S et al (2006) Information needs and experiences: an audit of UK cancer patients. Eur J Oncol Nurs 10:263–272PubMedCrossRef
15.
go back to reference Jenkins V, Fallowfield L, Saul J (2001) Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 84:48–51PubMedCrossRef Jenkins V, Fallowfield L, Saul J (2001) Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 84:48–51PubMedCrossRef
16.
go back to reference Perry S, Kowalski TL, Chang CH (2007) Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 5:24–37PubMedCrossRef Perry S, Kowalski TL, Chang CH (2007) Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 5:24–37PubMedCrossRef
17.
go back to reference Degner LF, Kristjanson LJ, Bowman D et al (1997) Information need and decisional preferences in women with breast cancer. JAMA 277:1485–1492PubMedCrossRef Degner LF, Kristjanson LJ, Bowman D et al (1997) Information need and decisional preferences in women with breast cancer. JAMA 277:1485–1492PubMedCrossRef
18.
go back to reference Mandelblatt J, Kreling B, Figeuriedo M, Feng S (2006) What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol 24:4908–4913PubMedCrossRef Mandelblatt J, Kreling B, Figeuriedo M, Feng S (2006) What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol 24:4908–4913PubMedCrossRef
19.
go back to reference Deber RB, Kraetschmer N, Urowitz S, Sharpe N (2007) Do people want to be autonomous patients? Preferred roles in treatment decision-making in several patient populations. Health Expect 10:248–258PubMedCrossRef Deber RB, Kraetschmer N, Urowitz S, Sharpe N (2007) Do people want to be autonomous patients? Preferred roles in treatment decision-making in several patient populations. Health Expect 10:248–258PubMedCrossRef
20.
go back to reference Wallberg B, Michelson H, Nystedt M et al (2000) Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients. Acta Oncol 39:467–476PubMedCrossRef Wallberg B, Michelson H, Nystedt M et al (2000) Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients. Acta Oncol 39:467–476PubMedCrossRef
21.
go back to reference Janz NK, Wren PA, Copeland LA et al (2004) Patient–physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol 22:3091–3098PubMedCrossRef Janz NK, Wren PA, Copeland LA et al (2004) Patient–physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol 22:3091–3098PubMedCrossRef
22.
go back to reference Lantz PM, Janz NK, Fagerlin A et al (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745–767PubMedCrossRef Lantz PM, Janz NK, Fagerlin A et al (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745–767PubMedCrossRef
23.
go back to reference Sabo B, St-Jacques N, Rayson D (2007) The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat 102:51–59PubMedCrossRef Sabo B, St-Jacques N, Rayson D (2007) The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat 102:51–59PubMedCrossRef
24.
go back to reference Caldon LJM, Walters SJ, Reed MWR (2007) Changing trends in the decision-making preferences of women with early breast cancer. Br J Surg (in press). doi: 10.1002/bjs.5964 Caldon LJM, Walters SJ, Reed MWR (2007) Changing trends in the decision-making preferences of women with early breast cancer. Br J Surg (in press). doi: 10.​1002/​bjs.​5964
25.
go back to reference Beaver K, Booth K (2002) Information needs and decision-making preferences: comparing findings for gynecological, breast and colorectal cancer. Eur J Oncol Nursing 11:409–416CrossRef Beaver K, Booth K (2002) Information needs and decision-making preferences: comparing findings for gynecological, breast and colorectal cancer. Eur J Oncol Nursing 11:409–416CrossRef
26.
go back to reference Katz SJ, Hawley ST (2007) From policy to patients and back: surgical decision-making for patients with breast cancer. Health Aff (Millwood) 26:761–769CrossRef Katz SJ, Hawley ST (2007) From policy to patients and back: surgical decision-making for patients with breast cancer. Health Aff (Millwood) 26:761–769CrossRef
27.
go back to reference Whelan T, Sawka C, Levine M et al (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581–587PubMedCrossRef Whelan T, Sawka C, Levine M et al (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581–587PubMedCrossRef
28.
go back to reference Keating NL, Guadagnoli E, Landrum MB et al (2002) Treatment decision making in early-stage breast cancer: should surgeons match patients’ desired level of involvement? J Clin Oncol 20:1473–1479PubMedCrossRef Keating NL, Guadagnoli E, Landrum MB et al (2002) Treatment decision making in early-stage breast cancer: should surgeons match patients’ desired level of involvement? J Clin Oncol 20:1473–1479PubMedCrossRef
29.
go back to reference Fallowfield L (1997) Offering choice of surgical treatment to women with breast cancer. Patient Educ Couns 30(3):209–214PubMedCrossRef Fallowfield L (1997) Offering choice of surgical treatment to women with breast cancer. Patient Educ Couns 30(3):209–214PubMedCrossRef
30.
go back to reference Fallowfield LJ, Hall A, Maguire P, Baum M, A’Hern RP (1994) Psychological effects of being offered choice of surgery for breast cancer. Br Med J 309:448–454 Fallowfield LJ, Hall A, Maguire P, Baum M, A’Hern RP (1994) Psychological effects of being offered choice of surgery for breast cancer. Br Med J 309:448–454
31.
go back to reference Al-Ghazal SK, Fallowfield L, Blamey RW (2000) Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 36:1938–1943PubMedCrossRef Al-Ghazal SK, Fallowfield L, Blamey RW (2000) Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 36:1938–1943PubMedCrossRef
32.
go back to reference Al-Ghazal SK, Fallowfield L, Blamey RW (1999) Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? Eur J Surg Oncol 25:571–573PubMedCrossRef Al-Ghazal SK, Fallowfield L, Blamey RW (1999) Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? Eur J Surg Oncol 25:571–573PubMedCrossRef
33.
go back to reference Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 26:17–19PubMedCrossRef Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 26:17–19PubMedCrossRef
34.
go back to reference Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271–2276PubMedCrossRef Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271–2276PubMedCrossRef
35.
go back to reference Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612–616PubMedCrossRef Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612–616PubMedCrossRef
36.
go back to reference Peto R, Davies C, on behalf of the ATLAS Collaboration (2007) ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women—preliminary results. Breast Cancer Res Treat 106 (suppl 1):abstract 48 Peto R, Davies C, on behalf of the ATLAS Collaboration (2007) ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women—preliminary results. Breast Cancer Res Treat 106 (suppl 1):abstract 48
37.
go back to reference Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885–1892PubMed Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885–1892PubMed
38.
go back to reference Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRef Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRef
39.
go back to reference Cox AC, Fallowfield LJ (2007) After going through chemotherapy I can’t see another needle. Eur J Oncol Nurs 11:43–48PubMedCrossRef Cox AC, Fallowfield LJ (2007) After going through chemotherapy I can’t see another needle. Eur J Oncol Nurs 11:43–48PubMedCrossRef
40.
go back to reference Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9PubMed Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9PubMed
41.
go back to reference Fellowes D, Fallowfield LJ, Saunders CM, Houghton J (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat 66:73–81PubMedCrossRef Fellowes D, Fallowfield LJ, Saunders CM, Houghton J (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat 66:73–81PubMedCrossRef
42.
go back to reference Cella D, Falowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284PubMedCrossRef Cella D, Falowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284PubMedCrossRef
43.
go back to reference Fallowfield L, Bliss JM, Porter LS et al (2006) Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917PubMedCrossRef Fallowfield L, Bliss JM, Porter LS et al (2006) Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917PubMedCrossRef
44.
go back to reference Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 28:6931–6940CrossRef Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 28:6931–6940CrossRef
45.
go back to reference Trialists’ Group ATAC (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer. First results of the ATAC randomized trial. Lancet 359:2131–2139 Trialists’ Group ATAC (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer. First results of the ATAC randomized trial. Lancet 359:2131–2139
46.
go back to reference Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef
47.
go back to reference Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271PubMedCrossRef Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271PubMedCrossRef
48.
go back to reference Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570PubMedCrossRef Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570PubMedCrossRef
49.
go back to reference Wengström Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V (2007) Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 16:462–468PubMedCrossRef Wengström Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V (2007) Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 16:462–468PubMedCrossRef
50.
go back to reference Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRef Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRef
51.
go back to reference Gaston CM, Mitchell G (2005) Information giving and decision-making in patients with advanced cancer: a cancer systematic review. Soc Sci Med 61:2252–2264PubMedCrossRef Gaston CM, Mitchell G (2005) Information giving and decision-making in patients with advanced cancer: a cancer systematic review. Soc Sci Med 61:2252–2264PubMedCrossRef
52.
go back to reference Grunfeld EA, Maher EJ, Browne S et al (2006) Advanced breast cancer patients’ perceptions of desicion making for palliative chemotherapy. J Clin Oncol 24:1090–1098PubMedCrossRef Grunfeld EA, Maher EJ, Browne S et al (2006) Advanced breast cancer patients’ perceptions of desicion making for palliative chemotherapy. J Clin Oncol 24:1090–1098PubMedCrossRef
53.
go back to reference Graydon J, Galloway S, Palmer-Wickham S et al (1997) Information needs of women during early treatment for breast cancer. J Adv Nurs 26:59–64PubMedCrossRef Graydon J, Galloway S, Palmer-Wickham S et al (1997) Information needs of women during early treatment for breast cancer. J Adv Nurs 26:59–64PubMedCrossRef
Metadata
Title
Treatment decision-making in breast cancer: the patient–doctor relationship
Author
L. J. Fallowfield
Publication date
01-12-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue Special Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0077-3

Other articles of this Special Issue 1/2008

Breast Cancer Research and Treatment 1/2008 Go to the issue

Optimizing Breast Cancer Patient

Are all aromatase inhibitors alike?

Optimizing Breast Cancer Patient

Editorial

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine